| Active substance | Osimertinib |
| Holder | AstraZeneca n.v./s.a. |
| Status | Running |
| Indication | For the treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 22/01/2025 |